Ratio of Omega-6/Omega-3 Polyunsaturated Fatty Acids Associated With Somatic and Depressive Symptoms in People With Painful Temporomandibular Disorder and Irritable Bowel Syndrome.
Ratio of Omega-6/Omega-3 Polyunsaturated Fatty Acids Associated With Somatic and Depressive Symptoms in People With Painful Temporomandibular Disorder and Irritable Bowel Syndrome.
复制标题
DOI：
10.1016/j.jpain.2022.04.006
复制
发表时间：
2022-10
期刊：
影响因子：
4
通讯作者：
Slade, Gary D.
中科院分区：
文献类型：
--
作者：
Sanders, Anne E.;Weatherspoon, E. Diane;Ehrmann, Brandie M.;Soma, Paul S.;Shaikh, Saame R.;Preisser, John S.;Ohrbach, Richard;Fillingim, Roger B.;Slade, Gary D.
躯体症状紊乱是疼痛性颞下颌关节紊乱病（TMD）最强的预测因子之一。相关的心理结构，如焦虑和抑郁，在临床试验中对omega-3多不饱和脂肪酸（PUFA）有治疗反应。这项横断面研究调查了501名成年人的社区样本中omega-6/omega-3 PUFA比例与躯体症状障碍和抑郁症状之间的关联，并确定这些关联是否与TMD或肠易激综合征（IBS）的成年人之间存在差异。液相色谱串联质谱定量循环红细胞中的PUFA。躯体症状和抑郁症量化使用症状自评量表-90-修订的分量表。分别通过临床检查和罗马III筛选问题确定是否存在TMD和IBS。在以躯体症状障碍为因变量的多变量线性回归模型中，omega-6/omega-3长链PUFA比率的标准化β系数为0.26（95%置信限（CL）：0.08，0.43）。当将抑郁症状建模为因变量时，标准化β系数为0.17（95% CL：0.01，0.34）。这两种关联在TMD病例和IBS病例中比在非病例中更强。未来降低omega-6/omega-3 PUFA比例的随机对照试验可能会考虑将躯体或抑郁症状作为TMD或IBS疼痛的治疗靶点。在疼痛性TMD或IBS患者中，n-6/n-3 PUFA的高比例与躯体症状障碍和抑郁症状呈正相关。在患有疼痛性TMD和IBS的人中，这两种心理困扰的测量值都有所升高。未来的随机临床试验将确定降低n-6/n-3比值是否能治疗疼痛。
Somatic symptom disturbance is among the strongest predictors of painful temporomandibular disorder (TMD). Related psychological constructs, such as anxiety and depression, respond therapeutically to omega-3 polyunsaturated fatty acids (PUFAs) in clinical trials. This cross-sectional study investigated associations between the omega-6/omega-3 PUFA ratio and somatic symptom disturbance and depressive symptoms in a community-based sample of 501 adults and determined whether these associations differed between adults with and without TMD or irritable bowel syndrome (IBS). Liquid chromatography tandem mass spectrometry quantified PUFAs in circulating erythrocytes. Somatic symptoms and depression were quantified using Symptom Checklist-90-Revised subscales. Presence or absence of TMD and IBS, respectively, were determined by clinical examination and Rome III screening questions. The standardized beta coefficient for the omega-6/omega-3 long-chain PUFA ratio was 0.26 (95% confidence limits (CL): 0.08, 0.43) in a multivariable linear regression model in which somatic symptom disturbance was the dependent variable. When modelling depressive symptoms as the dependent variable, the standardized beta coefficient was 0.17 (95% CL:0.01, 0.34). Both associations were stronger among TMD cases and IBS cases than among non-cases. Future randomized control trials that lower the omega-6/omega-3 PUFA ratio could consider somatic or depressive symptoms as a therapeutic target for TMD or IBS pain. In people with painful TMD or IBS, a high ratio of n-6/n-3 PUFA was positively associated with somatic symptom disturbance and depressive symptoms. Both measures of psychological distress were elevated in people with painful TMD and IBS. Future randomized clinical trials will determine whether lowering the n-6/n-3 ratio is therapeutic for pain.
登录
查看更多内容
影响因子：
5.9
作者：
Jiang L;Wang J;Xiong K;Xu L;Zhang B;Ma A
通讯作者：
Ma A
影响因子：
3.6
作者：
Balvers, Michiel G. J.;Verhoeckx, Kitty C. M.;Bijlsma, Sabina;Rubingh, Carina M.;Meijerink, Jocelijn;Wortelboer, Heleen M.;Witkamp, Renger F.
通讯作者：
Witkamp, Renger F.
影响因子：
3.4
作者：
da Rocha, Camilla M. M.;Kac, Gilberto
通讯作者：
Kac, Gilberto
影响因子：
3.5
作者：
Hollier, John M.;van Tilburg, Miranda A. L.;Shulman, Robert J.
通讯作者：
Shulman, Robert J.
影响因子：
7.1
作者：
BJERVE, KS;BRUBAKK, AM;VIK, T
通讯作者：
VIK, T